Abstract: Prostate cancer is a prevalent and controversial public health issue in the United States and Europe. Although the disease is common long-term prostate cancer specific morbidity and mortality tends to be low and treatments carry substantial potential for adverse effects and high costs. The prevalence of prostate cancer in China is markedly lower than in the US but demographic shifts may lead to substantial increases in prostate cancer among Chinese men. In this update, we will compare and contrast prostate cancer in Chinese versus American men. This will be followed by an update on pivotal trials reported out in 2017, the evolving role of MRI, updated guidelines for prostate cancer in 2017, evidence to support the use of active surveillance in appropriated selected patients, and lastly a brief primer on novel biomarkers in the prostate cancer space. Attendees should leave with a better understanding of the major issues and developments in the prostate cancer space.
Keywords: Prostate cancer; public health issue; biomarkers
Cite this abstract as: Shindel A. Prostate cancer 2017 update. Transl Androl Urol 2017;6(Suppl 3):AB001. doi: 10.21037/tau.2017.s001